TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04055636

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography with speckle tracking analysis.
Description: Transthoracic echocardiography with speckle tracking analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography with speckle tracking analysis.
Description: Transthoracic echocardiography with speckle tracking analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography with speckle tracking analysis.
Description: Transthoracic echocardiography with speckle tracking analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography with speckle tracking analysis.
Description: Transthoracic echocardiography with speckle tracking analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: 48-hour ECG monitoring.
Description: Ambulatory 48-hour electrocardiography monitoring.

Intervention type: DIAGNOSTIC_TEST
Intervention: 48-hour ECG monitoring.
Description: Ambulatory 48-hour electrocardiography monitoring.

Intervention type: DIAGNOSTIC_TEST
Intervention: 48-hour ECG monitoring.
Description: Ambulatory 48-hour electrocardiography monitoring.

Intervention type: DIAGNOSTIC_TEST
Intervention: 48-hour ECG monitoring.
Description: Ambulatory 48-hour electrocardiography monitoring.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples analysis.
Description: Analysis of blood samples for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples analysis.
Description: Analysis of blood samples for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples analysis.
Description: Analysis of blood samples for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples analysis.
Description: Analysis of blood samples for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
Study: NCT04428138

Intervention type: DIAGNOSTIC_TEST
Intervention: In-office vascular visit
Description: Every patient will undergo a complete physical examination in order to detect any clinical or sub clinical vascular disease.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echo duplex scan of arterial system
Description: Every patient will undergo a complete echo duplex scan in order to detect any morphological or hemodynamic alteration of aorta, carotid arteries and lower limb arteries.
Study: NCT03212677

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: Standard-of-care therapy for iron deficiency anaemia

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: Standard-of-care therapy for iron deficiency anaemia

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: Standard-of-care therapy for iron deficiency anaemia

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: Standard-of-care therapy for iron deficiency anaemia

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IHAT
Description: IHAT is a nanoparticle composed of three General Regarded As Safe (GRAS) substances, iron hydroxide, tartaric acid and adipic acid. The particle itself resembles the normal metabolite ferritin, which is a larger polyatomic particle. Like ferritin, IHAT can be absorbed by endocytosis, but dissociates within the enterocyte and is subsequently metabolized as ferrous iron.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aspiron
Description: Aspiron is a product of the natural fermentation of Koji (Aspergillus oryzae) in the presence of ferrous sulfate. The iron-rich koji biomass is heated, harvested and dried which results in the inactivation of Koji powder that contains 8-10% iron. Koji (A. oryzae) is widely used for making such foods as soy sauce, tempeh, miso, and for producing food-grade α-amylase, and is considered safe by Joint Food and Agriculture Organization of the United Nations (FAO)/WHO Committee on Food Additives and has been accepted as a GRAS constituent of food.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cornstarch
Study: NCT02771639

Intervention type: PROCEDURE
Intervention: Hip arthroplasty
Description: Treatment with a hip arthroplasty (semi- or total hip arthroplasty) for a displaced femoral neck fracture
Study: NCT01860417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic Mesenchymal Stromal Cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine
Study: NCT05298852

Intervention type: DIAGNOSTIC_TEST
Intervention: High resolution computed tomography of the chest
Description: All participants were subjected to High resolution computed tomography of the chest.
Study: NCT03779997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-based DOT Application
Description: Participants will be asked to record daily videos of themselves confirming daily ingestion of their buprenorphine. Clinical staff (i.e. physicians, nurses and medical assistants) of patients enrolled in the intervention group will be given training and the opportunity to review medication taking videos.
Study: NCT04554433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol with Asprin
Description: Group ( A ) which will receive the new protocol will be categorized into sub-groups according to the medical conditions , inclusion criteria , investigations and symptoms .~1. Inhaling alcohol vapor through nostrils .~2. Inhalation of Alcohol vapor driven by Oxygen .~3. Inhalation of Alcohol vapor driven by oxygen in case of ARDS.~4. Ethyl Alcohol infusion into the airway . Investigations will be made before starting the protocol and follow up data will be collected every day .~Follow up test will be done according to the schedule . PCR test will be done according to the duration of each technique to evaluate the final results .
Study: NCT04086472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clesrovimab
Description: Single dose of clesrovimab administered via IV infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clesrovimab
Description: Single dose of clesrovimab administered via IV infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clesrovimab
Description: Single dose of clesrovimab administered via IV infusion.
Study: NCT04207359

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol.
Study: NCT02105207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound
Description: Lung ultrasound evaluation is performed after clinical assessment and before chest radiography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Chest Radiography is performed after clinical evaluation without using ultrasound assessment
Study: NCT04086472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clesrovimab
Description: Single dose of clesrovimab administered via IV infusion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0.9% sodium chloride, USP sterile saline) administered via IV infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV-A Memphis 37b
Description: Approximately 4Log10 plaque-forming units (PFU)/mL RSV-A virus inoculation strain Memphis 37b administered via intranasal inoculation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV-A Memphis 37b
Description: Approximately 4Log10 plaque-forming units (PFU)/mL RSV-A virus inoculation strain Memphis 37b administered via intranasal inoculation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV-A Memphis 37b
Description: Approximately 4Log10 plaque-forming units (PFU)/mL RSV-A virus inoculation strain Memphis 37b administered via intranasal inoculation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV-A Memphis 37b
Description: Approximately 4Log10 plaque-forming units (PFU)/mL RSV-A virus inoculation strain Memphis 37b administered via intranasal inoculation.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RSV-A Memphis 37b
Description: Approximately 4Log10 plaque-forming units (PFU)/mL RSV-A virus inoculation strain Memphis 37b administered via intranasal inoculation.
Study: NCT02624102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trial based cognitive therapy
Description: Patients with MDD, in use of antidepressants plus Trial Based Cognitive Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Patients with MDD, in use of antidepressants plus Behavioral Activation

Intervention type: DRUG
Group type: OTHER
Intervention: Antidepressants
Description: Patients with MDD, in use of antidepressants (fluoxetine, citalopram, escitalopram, bupropion, etc.) without psychotherapy.
Study: NCT00667342

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Monoclonal Antibody against vascular endothelial growth factor (VEGF). Given intravenously (IV).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Monoclonal Antibody against vascular endothelial growth factor (VEGF). Given intravenously (IV).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Monoclonal Antibody against vascular endothelial growth factor (VEGF). Given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Participants undergo definitive surgery and assessment of histologic response at week 10.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Participants undergo definitive surgery and assessment of histologic response at week 10.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Participants undergo definitive surgery and assessment of histologic response at week 10.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation therapy delivered for positive margins or intralesional resections.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation therapy delivered for positive margins or intralesional resections.
Study: NCT06129812

Intervention type: DRUG
Intervention: Neoadjuvant treatment
Description: Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.

Intervention type: DRUG
Intervention: Neoadjuvant treatment
Description: Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.
Study: NCT03394508

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALK diluent 0,3% human albumin
Description: Intralymphatic injection with 0.1 ml. 3 injections with 4-5 weeks interval
Study: NCT01107171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tang-min-ling pills low dosage
Description: low dosage:6g Tang-min-ling pills every time,by 3 times every day for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tang-min-ling pills high dosage
Description: high dosage:12g Tang-min-ling pills every time,by 3 times every day for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tang-min-Ling pills analogue 6g,tid,po
Study: NCT03726528

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurements of left ventricular pressure and volume
Description: Patients with suspected Takotsubo syndrome (typical ballooning in left ventriculography without significant obstructive coronary artery disease that sufficiently explains the contraction abnormalities) will undergo continuous online measurements of left ventricular pressure and volume using conductance catheters. Cardiac magnetic resonance (CMR) imaging will be performed in patients without contraindications for optimized morphological characterization and exclusion of important differential diagnoses.
Study: NCT00279435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: visilizumab
Study: NCT02930499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalomatrix extra-cellular matrix
Description: An exta-cellular matrix made from hyaluronic acid

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex wound dressing
Description: A siliconized non-adhesive foam wound dressing
Study: NCT02044263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet CBT-i SHUTi
Description: Computer program SHUTi is based on the same theoretical model of insomnia and involves the same interventions as ordinary CBT-I: a structured treatment focusing on education, behaviors and cognitions. Specifically, CBT-I usually consists of one or more of the following: psychoeducation about sleep, sleep restriction therapy, stimulus control, relaxation techniques, and challenging beliefs and perception of sleep.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: face-to-face CBT-i
Study: NCT06129812

Intervention type: DRUG
Intervention: Neoadjuvant treatment
Description: Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.
Study: NCT04412941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myofunctional exercises
Description: Myofunctional exercises: Respiratory rehabilitation exercises with diaphragmatic breathing, thoracic mobilization exercises and manual pompage techniques, followed by manual trigger point therapy techniques, that were identified by palpation following the guidelines provided by Travell and Simons trigger point manual, the accessory inspiratory muscles like pectoralis minor muscle, scapula elevator muscle, Sternocleidomastoid muscle.~Home oropharyngeal exercises: at every patient will be taught oropharyngeal exercises to perform at home twice a day (the duration of 15 minutes each session) involving in particular exercises for soft palate, tongue, facial and genio-glosso muscle.~The rules of sleep hygiene: a list of behaviours that physiologically promote a good night's sleep.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The rules of sleep hygiene
Description: The rules of sleep hygiene: a list of behaviours that physiologically promote a good night's sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The rules of sleep hygiene
Description: The rules of sleep hygiene: a list of behaviours that physiologically promote a good night's sleep.
Study: NCT04904510

Intervention type: DIAGNOSTIC_TEST
Intervention: INDICAID™ COVID-19 Rapid Antigen Test
Description: The diagnostic assay will be compared to a EUA SARS-CoV-2 assay
Study: NCT01956578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercise Cohort
Description: All patients enrolled will be asked to wear a respiration band and perform a series of breathing exercises.
Study: NCT01127256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zonisamide
Description: Initial dose was 100mg/day, increased by 100mg. The maximum dose was 600mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbamazepine
Description: Initial dose was 100mg/day, increased by 200mg every 1 week to 600mg/day. The maximum dose was 1200mg/day.
Study: NCT02885545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Watchman
Description: If the patient is randomized to the Intervention Arm of the study the Watchman device will be implanted into the left atrial appendage of the heart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continued therapy with the prescribed oral anticoagulant
Description: If the patient is randomized to the control arm of the study, they will continue taking the oral anticoagulant that has been prescribed (vitamin K antagonist, Apixiban 2.5mg bid or Rivaroxaban 15mg od)
Study: NCT00692692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DermaMatrix
Description: experimental group with DermaMatrix acellular dermis over tissue expanders in addition to skin/soft tissue and muscle to allow for more natural appearing breast and prevention of complications
Study: NCT01479634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard ART
Description: Standard Ugandan 3-drug antiretroviral therapy regimen consistent with current practices

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study-Provided ART
Description: Study provided drugs:~1. Truvada® (one tablet PO daily of fixed dose combination consisting of tenofovir disoproxyl fumarate \[TDF\] and emtricitabine \[FTC\]) PLUS~2. Efavirenz \[EFV\]
Study: NCT03752723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: i.m.
Study: NCT00692692

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard of care tissue expander breast reconstruction surgery after mastectomy
Description: standard of care using skin/soft tissue and muscle coverage of tissue expander for breast reconstruction after mastectomy without acellular dermal matrix
Study: NCT03752723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: i.m.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab(KEYTRUDA®)
Description: i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab(KEYTRUDA®)
Description: i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: i.v.
Study: NCT03348761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS group
Study: NCT02200705

Intervention type: DEVICE
Group type: OTHER
Intervention: Ice-Sense3TM/ ProSenseTM
Study: NCT02703519

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resection of uterine scar tissue
Description: resection of uterine scar tissue of a previous cesarean section during a second cesarean section
Study: NCT01776749

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SubQ
Description: Spinal Cord Stimulation (SCS) and subcutaneous (SubQ) stimulation SCS trial stimulation: Implantation of the Octad lead in the epidural space. The lead implantation in the epidural space is performed under local anesthesia using a standard percutaneous technique. A key element to the technical success of an SCS procedure is the accurate placement of the lead, which results in paresthesia covering the patients' painful areas. This depends on the patients' feedback during intra-operative testing. Therefore, it is important that the patient is awake and fully cooperative during the trial stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SubQ
Description: Spinal Cord Stimulation (SCS) and subcutaneous (SubQ) stimulation SCS trial stimulation: Implantation of the Octad lead in the epidural space. The lead implantation in the epidural space is performed under local anesthesia using a standard percutaneous technique. A key element to the technical success of an SCS procedure is the accurate placement of the lead, which results in paresthesia covering the patients' painful areas. This depends on the patients' feedback during intra-operative testing. Therefore, it is important that the patient is awake and fully cooperative during the trial stimulation.
Study: NCT03240809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: 140 mg SC dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: 70 mg SC dose
Study: NCT01077167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Description: Oral dosing twice each day or three times each day, depending on the cohort assignment, of Omecamtiv mecarbil for 8 days. Omecamtiv mecarbil comes in 2 formulations: modified release and immediate release, and the formulation given will depend on the cohort assignment.
Study: NCT03497000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCTA-guided Photodynamic therapy
Description: Half-dose photodynamic therapy using verteporfin under the guidance of OCTA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICGA-guided Photodynamic therapy
Description: Half-dose photodynamic therapy using verteporfin under the guidance of ICGA
Study: NCT02484131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational materials/mail
Description: Participants in this group will receive any educational materials by mail during hte follow-up period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational materials/participant choice
Description: Participants in this group will not receive any educational materials by participant choice during hte follow-up period.
Study: NCT03381807

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAESCs
Description: 5\*10\^7 hAESCs is infused into uterine cavity with TCRA on Day0, Day7 and after the first menstruation
Study: NCT00976859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Modification
Description: Research via internet concerning the frequency of skin exchange and disputation of the collected information; in the guided imagery modification the therapist instructs the patient to imagine the feeling of being contaminated and the process of peeling off their former contaminated skin and the maturing of hundreds of new clean skin cells

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Waitlist control group
Description: Patients in the wait list control group are treated after a waiting period of five weeks
Study: NCT04242901

Intervention type: DIAGNOSTIC_TEST
Intervention: Faecal Immunochemical Test - OC Sensor, Eiken, Tokyo
Description: Quantitative Faecal Immunochemical Test - OC Sensor, Eiken, Tokyo
Study: NCT01260194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab [Herceptin]
Description: Loading dose of 8 mg/kg on day 1, followed by 6 mg/kg intravenous infusion every 3 weeks until disease progression in combination with standard chemotherapy